A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • 2013 Methodology for the 2014 Access to Medic...
Publication - published on 29 Oct 2013

2013 Methodology for the 2014 Access to Medicine Index

The 2013 Methodology for the 2014 Access to Medicine Index describes the methodology for the next Index and how it was developed. 

The methodology for the 2014 Access to Medicine Index remains largely the same as the methodology for the previous Index. The 2014 Index will use the same framework for analysis, which continues to be constructed along seven Technical Areas with indicators measured across four Strategic Pillars.

The weights within the framework remain unchanged and most of the indicators remain the same, though the number of indicators has been reduced. The geographic scope and disease scope have been expanded.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |